Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source highlights potential treatments for post-finasteride syndrome, including allopregnanolone, trazodone, antipsychotic drugs, and hormonal therapies, but notes further research is necessary to confirm their efficacy.

This study indicates that finasteride use may lower bladder cancer incidence, while androgen suppression therapy improves recurrence-free survival but not other survival outcomes in bladder cancer patients.

This article discusses androgenetic alopecia in men and reports that finasteride at 1 mg/day for 24 months is generally well tolerated and may effectively inhibit hair loss.

This study found that Italian dermatologists commonly prescribe 1 mg/day finasteride for androgenetic alopecia despite reported sexual side effects, due to its perceived long-term efficacy.

This study observed some differences in clinical outcomes when comparing CPA with spironolactone, flutamide, and finasteride, but no differences with other therapies, possibly due to small study size and non-standardized assessments; adverse effects could not be fully compared across treatments.

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This animal study found that finasteride, a 5-alpha reductase type 2 inhibitor, decreased dihydrotestosterone levels and c-Fos protein activation in the rat brain, but these effects may diminish after discontinuing the drug.

In this study, three patients with extensive alopecia areata receiving ustekinumab treatment showed significant hair regrowth and decreased inflammation over 20 weeks, suggesting potential targeted treatment for this condition.

Finasteride and dutasteride can affect sexual function in BPH patients.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This study found that combination therapy with 5% minoxidil and 0.5% anthralin led to hair regrowth in some patients with severe treatment-resistant alopecia areata, but also caused mild to moderate irritant dermatitis in all participants.

This study found that a combination of low-dose isotretinoin and oral azithromycin pulse effectively treats severe acne with an acceptable side effect profile and relatively low relapse rates.

This study found that the herbal combination PRO 160/120 significantly improved nocturnal voiding frequency in patients with moderate-to-severe LUTS/BPH compared to placebo, with similar effectiveness to tamsulosin and finasteride.

This study found that using a contrast agent in Microbeam Radiation Therapy simulations increased the target dose but concluded that using a linear accelerator as an X-ray source did not preserve MRT advantages.

This study evaluated the safety and effectiveness of HASHA, a new hyaluronic acid injectable, for chin augmentation in adults with chin retrusion. HASHA significantly improved chin appearance and satisfaction over 12 months compared to controls, with only mild or moderate transient adverse events.

This study suggests spironolactone, particularly when combined with an oral contraceptive or dexamethasone, may reduce hair symptoms in women with hirsutism, but it should be avoided during pregnancy and in women with a family history of breast cancer.

In this study, spironolactone was found to be a safe and effective treatment for acne in women over 25 with abnormal hormone levels, while younger women with normal hormone levels showed less response.

This study found that topical phenylephrine, an α1-AR agonist, significantly reduced hair shedding and increased epilation force threshold in women experiencing traction alopecia during cosmetic procedures.

Smart microneedles improve hair loss treatment by delivering drugs precisely with fewer side effects.

This study found that tildacerfont treatment in males with congenital adrenal hyperplasia reduced androgen levels and improved markers of testicular function, suggesting potential benefits for male reproductive health.

This study explored a new dutasteride nanocarrier for alopecia therapy, concluding that ingredient concentration is key to achieving the optimal particle size, stability, and skin permeation for extended drug release.

This study describes characteristics and outcomes for adults initiating ritlecitinib for severe alopecia areata, highlighting increased hair regrowth and physician satisfaction with longer treatment durations, despite ongoing psychosocial impacts like embarrassment and anxiety among patients.

This review reports that while finasteride effectively treats androgenetic alopecia and benign prostatic hyperplasia, persistent adverse effects on sexual, psychological, and metabolic health have been noted, highlighting the need for ongoing research and careful risk assessment for safer clinical usage.

In this study, participants receiving a 50-mg maintenance dose of ritlecitinib reported greater improvements in emotional and activity limitations due to hair loss by Week 48 compared to those on a 10-mg dose.

In this case report, an 11-year-old girl with alopecia totalis initially treated with minoxidil experienced hypertrichosis, which reversed upon stopping the medication; hair regrowth on the scalp was achieved with tofacitinib after minoxidil discontinuation.